Alexis Peyroles - OSE Pharma Consultant
| OSE Stock | EUR 7.06 0.05 0.71% |
Executive
Mr. Alexis Peyroles was appointed as Chief Executive Officer of OSE Immunotherapeutics SA as of March 28, 2019. He previously served as Deputy CEO and Chief Financial Officer at the company. He has more than 15 years of management and financial control experience, notably acquired internationally. He joined SanofiAventis in 1996, where he was a financial controller in Japan, and head of financial control for the baltic states. He then became head of activities for Business Development for Eastern Europe. In 2005 he joined the Guerbet group as Financial Control Manager. In 2009, he became CEO for Latin America, based in Brazil. He was involved in the OSE Pharma project from 2013. He is graduate of EDHEC and holds MBA from Imperial College London. since 2019.
| Age | 49 |
| Tenure | 5 years |
| Professional Marks | MBA |
| Phone | 33 2 28 29 10 10 |
| Web | https://www.ose-immuno.com |
OSE Pharma Management Efficiency
The company has return on total asset (ROA) of (0.0528) % which means that it has lost $0.0528 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1482) %, meaning that it generated substantial loss on money invested by shareholders. OSE Pharma's management efficiency ratios could be used to measure how well OSE Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 2 records | EXECUTIVE Age | ||
| Thierry Paper | Biosynex | N/A | |
| Benoit Dinechin | Kalray SA | N/A | |
Management Performance
| Return On Equity | -0.15 | |||
| Return On Asset | -0.0528 |
OSE Pharma SA Leadership Team
Elected by the shareholders, the OSE Pharma's board of directors comprises two types of representatives: OSE Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of OSE. The board's role is to monitor OSE Pharma's management team and ensure that shareholders' interests are well served. OSE Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, OSE Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Brangre Vasseur, Chief ImmunoOncology | ||
| Alain MD, Medical Director | ||
| Silvia MD, Head Devel | ||
| Nicolas Poirier, Scientific Director | ||
| AnneLaure AutretCornet, Chief Financial and Administrative Officer | ||
| JeanPascal PharmD, Chief Person | ||
| Dominique MD, Chairman Founder | ||
| Alexis Peyroles, Consultant | ||
| Julien Perrier, Chief Commercial Officer | ||
| Linda MSc, Chief Officer |
OSE Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is OSE Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.15 | |||
| Return On Asset | -0.0528 | |||
| Profit Margin | (0.22) % | |||
| Operating Margin | (0.25) % | |||
| Current Valuation | 128.18 M | |||
| Shares Outstanding | 18.44 M | |||
| Shares Owned By Insiders | 39.03 % | |||
| Shares Owned By Institutions | 1.81 % | |||
| Price To Earning | 10.60 X | |||
| Price To Book | 2.64 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in OSE Stock
OSE Pharma financial ratios help investors to determine whether OSE Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in OSE with respect to the benefits of owning OSE Pharma security.